Newsroom
October 3, 2024
In the study of uncommon congenital disorders, collaboration is key to potential new insights and discoveries. The Gabriella Miller Kids First Pediatric Research Program Data Resource Center announced in September the public release of three comprehensive datasets related to childhood cancers and congenital disorders, one of which was provided by The University of Texas […]
October 3, 2024
Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2). This gene is responsible for providing instructions on creating certain proteins and is known to have a tumor-suppressive function. A study published October 2 in Nature is the first to explain the pathway […]
October 1, 2024
Pancreatic ductal adenocarcinoma (PDAC), a certain type of pancreatic cancer, is a ruthless killer with an average five-year survival rate of less than 10%. Most patients are diagnosed at a late stage when the cancer has already spread throughout their bodies. And the problem is only growing worse. By 2030, pancreatic cancer is expected […]
September 30, 2024
Charles P. France, PhD, to lead methocinnamox drug development program The University of Texas Health Science Center at San Antonio (UT Health San Antonio) was awarded a $12 million cooperative agreement (U01) from the National Institutes of Health’s National Institute on Drug Abuse to further develop methocinnamox (MCAM) as a treatment for opioid use disorder. […]
September 19, 2024
The University of Texas Health Science Center at San Antonio (UT Health San Antonio) was recently awarded a $12.6 million program project grant (P01) from the National Institutes of Health’s National Cancer Institute to expand collaborative efforts to explore the biological mechanisms of BRCA1, BRCA2 and related tumor suppressors and to shed light on potential […]
September 9, 2024
Ronald Rodriguez, MD, PhD, professor of medical education and urology at Joe R. and Teresa Lozano Long School of Medicine at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) discovers the combination of valproic acid and docosahexaenoic acid (DHA) may reduce the risk of contracting COVID-19 and lessen its severity, according to […]
